Use of the abatacept in a patient with psoriatic arthritis.

Abstract

Psoriatic arthritis (PA) is an inflammatory seronegative arthritis of unknown origin. Classically, PA has five clinical forms, and asymmetric oligoarthritis is the most common type. We describe the case of a patient with PA refractory to disease-modifying drugs, who developed drug-induced hepatitis after chemoprophylaxis with isoniazid, administered prior to the treatment with an anti-TNFα agent. Due to the risk of activating latent tuberculosis with the administration of anti-TNFα and hepatotoxicity onset caused by the TB treatment and based on the fact that the treatment of PA is similar to the treatment of rheumatoid arthritis, a decision was made to use the empirical treatment with abatacept. Approximately twenty days after the second infusion of the drug, the patient showed clinical improvement, resolution of the arthritis, almost complete disappearance of the skin lesions and improvement of anemia and inflammatory tests.

• Authors: Carlos Ewerton Maia Rodrigues, Francisco José Fernandes Vieira, Maria Roseli Monteiro Callado, Kirla Wagner Poti Gomes, José Eyorand Castelo Branco de Andrade, Walber Pinto Vieira
• Journal: Revista brasileira de reumatologia (Rev Bras Reumatol) 2010 May-Jun Vol. 50 Issue 3 Pg. 340-5 ISSN: 1809-4570 [Electronic] Brazil
• PMID: 21125170 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunoconjugates
• Tumor Necrosis Factor-alpha
• Abatacept

Topics

• Abatacept
• Arthritis, Psoriatic (drug therapy)
• Female
• Humans
• Immunoconjugates (therapeutic use)
• Middle Aged
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)